MedKoo Cat#: 412146 | Name: BN 52211

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BN 52211 is a newly synthesized aza alkyl lysophosplipid of MW 536. BN 52211 is a phospholipid compound with direct cytotoxic and immunomodulatory activity against a variety of human tumour cell lines

Chemical Structure

BN 52211
BN 52211
CAS#136533-74-9

Theoretical Analysis

MedKoo Cat#: 412146

Name: BN 52211

CAS#: 136533-74-9

Chemical Formula: C28H61N2O5P

Exact Mass: 536.4318

Molecular Weight: 536.78

Elemental Analysis: C, 62.65; H, 11.45; N, 5.22; O, 14.90; P, 5.77

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BN-52211; BN52211; BN 52211
IUPAC/Chemical Name
3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N,9-tetramethyl-, hydroxide, inner salt, 4-oxide
InChi Key
IMBDJLSSCGCJMU-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H61N2O5P/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-29(2)26-28(33-6)27-35-36(31,32)34-25-24-30(3,4)5/h28H,7-27H2,1-6H3
SMILES Code
CCCCCCCCCCCCCCCCCCN(C)CC(OC)COP(OCC[N+](C)(C)C)([O-])=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 536.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gan XH, Bonavida B. Preferential induction of TNF-alpha and IL-1beta and inhibition of IL-10 secretion by human peripheral blood monocytes by synthetic aza-alkyl lysophospholipids. Cell Immunol. 1999 May 1;193(2):125-33. doi: 10.1006/cimm.1999.1457. PMID: 10222054. 2: Diomede L, Piovani B, Re F, Principe P, Colotta F, Modest EJ, Salmona M. The induction of apoptosis is a common feature of the cytotoxic action of ether- linked glycerophospholipids in human leukemic cells. Int J Cancer. 1994 Jun 1;57(5):645-9. doi: 10.1002/ijc.2910570506. PMID: 8194871. 3: Principe P, Broquet C, Paull K, Grever M, Coulomb H, Huchet M, Menciahuerta J, Braquet P. New antineoplastic aza-phospholipids - synthesis, in-vitro cytotoxicity and differential cellular-sensitivity against 70 human tumor-cell lines. Int J Oncol. 1994 Jan;4(1):29-36. PMID: 21566885. 4: Principe P, Sidoti C, Coulomb H, Broquet C, Braquet P. Tumor cell kinetics following long-term treatment with antineoplastic ether phospholipids. Cancer Detect Prev. 1994;18(5):393-400. PMID: 7812986. 5: Diomede L, Principe P, Domingo M, Broquet C, Chabrier P, Braquet P, Salmona M. Effect of paf antagonists on the cytotoxic activity of antineoplastic ether phospholipids. Int J Oncol. 1993 May;2(5):777-80. doi: 10.3892/ijo.2.5.777. PMID: 21573625. 6: Pignol B, Chaumeron S, Coulomb H, Maisonnet T, Vandamme B, Broquet C, Mencia- Huerta JM, Braquet P. Immunomodulatory activity of two new aza alkyl phospholipid antineoplastic drugs. Anticancer Drugs. 1992 Dec;3(6):599-608. doi: 10.1097/00001813-199212000-00007. PMID: 1288731. 7: Principe P, Coulomb H, Broquet C, Braquet P. Evaluation of combinations of antineoplastic ether phospholipids and chemotherapeutic drugs. Anticancer Drugs. 1992 Dec;3(6):577-87. doi: 10.1097/00001813-199212000-00004. PMID: 1288728. 8: Sidoti C, Principe P, Vandamme B, Broquet C, Braquet P. Cytostatic activity of new synthetic anti-tumor aza-alkyllysophospholipids. Int J Cancer. 1992 Jul 9;51(5):712-7. doi: 10.1002/ijc.2910510509. PMID: 1612779. 9: Morimoto H, Broquet C, Principe P, Mencia-Huerta JM, Braquet P, Bonavida B. Cytotoxic activity of synthetic aza alkyl lysophospholipids against drug sensitive and drug resistant human tumor cell lines. Anticancer Res. 1991 Nov- Dec;11(6):2223-9. PMID: 1776863.